SITE003 (CAN) › SITE003-0013

SITE003-0013

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2025-08-31

enrolled

AEs

Serious

Dropout signal

–

Adverse events

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-01-04 (study day 296); relationship: not assessed; serious criteria: hospitalization

severe serious assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-03 (study day 295); relationship: not assessed

mild assessed

Grade 1 Hepatitis — outcome: RECOVERED/RESOLVED; onset 2022-06-13 (study day 91); relationship: not assessed

mild assessed

Data queries

No data queries. Open queries would appear here for this patient.